University of Plymouth has launched Vaccine Group, a vaccine developer based on research by Michael Jarvis, associate professor in virology and immunology.

University of Plymouth created a new spinout, Vaccine Group, on Tuesday to commercialise vaccines for use in infection control and for diseases that spread from animals to humans.

The spinout’s creation was supported by commercialisation firm Frontier IP Group as part of its existing partnership agreement with the institution. Frontier IP obtained a 21% stake in the business.

Vaccine Group is based on technology developed by Michael Jarvis, associate professor in virology and immunology, and will aim to create vaccines…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?